Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascletis PharmaHKSE:01672 -2.24%38 PS Ratio is 5,010.00 as of Aug. 22, 2026, which is 11935% above its 10-year median of 41.63. GuruFocus rates HKSE:01672 with a GF Score™ of 38/100 and a GF Value™ of HK$0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Ascletis Pharma ranks worse than 98.6% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ascletis Pharma's share price is HK$10.02.
Ascletis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00. Hence, Ascletis Pharma's PS Ratio for today is 5,010.00.
The historical rank and industry rank for Ascletis Pharma's PS Ratio or its related term are showing as below:
HKSE:01672'
s PS Ratio Range Over the Past 10 Years
Min: 13.45 Med: 41.63 Max: 17740
Current: 5010
During the past 10 years, Ascletis Pharma's highest PS Ratio was 17740.00. The lowest was 13.45. And the median was 41.63.
HKSE:01672's PS Ratio is ranked worse than 98.6% of 930
companies
in the Biotechnology industry
Industry Median: 9.55
vs HKSE:01672: 5010.00
Ascletis Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Ascletis Pharma was 100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -67.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -55.50% per year.
During the past 10 years, Ascletis Pharma's highest 3-Year average Revenue per Share Growth Rate was 77.00% per year. The lowest was -77.30% per year. And the median was -26.50% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ascletis Pharma PS Ratio Related Terms
Ascletis Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01672 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Ascletis Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ascletis Pharma's Share Price of today is HK$10.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascletis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ascletis Pharma (HKSE:01672) has a PS Ratio of 5,010.00 as of Aug. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascletis Pharma and its competitors. This is 11935% above median its historical median of 41.63. Over the past decade, Ascletis Pharma's PS Ratio has ranged from 13.45 to 17,740.00. According to the industry distribution chart, Ascletis Pharma ranks #917 out of 930 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Ascletis Pharma's PS Ratio too high?
Ascletis Pharma's current PS Ratio of 5,010.00 is 11935% above median its 10-year median of 41.63. Over the past 10 years, this metric has ranged from a low of 13.45 to a high of 17,740.00. The Biotechnology industry median PS Ratio is 9.55. Ascletis Pharma's value of 5,010.00 is 52360.7% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #917 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #917 out of 930 companies for PS Ratio. This places Ascletis Pharma in the lower half of its industry. The industry median PS Ratio is 9.55. Ascletis Pharma's value of 5,010.00 is 52360.7% above this benchmark. Historically, Ascletis Pharma's own PS Ratio has ranged from 13.45 to 17,740.00 over the past decade. While the company's 10-year median is 41.63 vs. the industry median of 9.55, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current PS Ratio of 5,010.00 is 52360.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current PS Ratio is 5,010.00, which is 11935% above median its own 10-year median of 41.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (HKSE:01672) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$10.02 — trading 7057.1% above its estimated fair value. The current PS Ratio is 5,010.00, which is 11935% above median its 10-year median of 41.63 and 52360.7% above the Biotechnology industry median of 9.55. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ascletis Pharma (HKSE:01672), the current PS Ratio is 5,010.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (HKSE:01672) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of HK$10.02 is trading 7057.1% above its estimated GF Value™ of HK$0.14.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for HKSE:01672:
PS Ratio: 5,010.00 (11935% above median its 10-year median of 41.63)
GF Value™: HK$0.14 vs. price of HK$10.02 (7057.1% above fair value)
Industry Position: 52360.7% above the Biotechnology median (#917 of 930)
No single metric tells the full story. See the HKSE:01672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for HKSE:01672
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01672 has been successfully added to your 
